{
    "nct_id": "NCT03930953",
    "official_title": "A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).",
    "inclusion_criteria": "* History of Non-Hodgkin's Lymphoma (NHL) with relapsed or refractory disease\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Life expectancy ≤ 2 months\n* Received prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to starting CC-99282, whichever is shorter\n* Is on chronic systemic immunosuppressive therapy or corticosteroids or has clinically significant graft-versus-host disease (GVHD)\n* Impaired cardiac function or clinically significant cardiac disease\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}